Turck Dominique, Bohn Torsten, de la Montaña Cámara Hurtado María, Castenmiller Jacqueline, De Henauw Stefaan, Jos Ángeles, Maciuk Alexandre, Mangelsdorf Inge, Mcnulty Breige, Naska Androniki, Pentieva Kristina, Siani Alfonso, Thies Frank, Aguilera Gómez Margarita, Frenzel Thomas, McArdle Harry J, Moldeus Peter, Neuhäuser-Berthold Monika, Schlatter Josef Rudolf, van Loveren Henk, Matijević Leonard, Hirsch-Ernst Karen Ildico
EFSA J. 2025 Jul 24;23(7):e9534. doi: 10.2903/j.efsa.2025.9534. eCollection 2025 Jul.
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the safety of inulin-propionate ester as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF, which is the subject of the application, is a compound constituted by a natural polymer composed mainly of fructose moieties, polysaccharide inulin (65%-95% w/w), esterified with a short-chain fatty acid (SCFA) moiety, propionic acid (5%-35% w/w). The NF is synthesised by the chemical reaction of inulin with propionic anhydride, under alkaline conditions and controlled temperature. The target population for the NF is the general population and it is intended to be used as an ingredient in cereal bars and fruit smoothie type beverages. Based on the provided studies investigating the metabolic fate of the NF, the Panel considers that the NF is not absorbed intact, but it is metabolised mainly in the large intestine to inulin and propionate which then exhibit normal metabolic fate of non-digestible dietary fibre and SCFA, respectively. Taking into account physico-chemical properties of the NF, the production process and metabolic fate of the NF, which do not raise safety concerns, and given that propionic acid and its salts were previously assessed by EFSA ANS Panel (2014), as well as that a large body of safety data were available on inulin, the Panel considers that no genotoxicity and subchronic toxicological studies are required on the NF. Despite the limitations of the provided human studies (primarily designed to investigate efficacy endpoints), the Panel notes that the NF, at doses up to 20 g/day for durations up to 12 months, appears to be generally well-tolerated. The Panel concludes that the NF, inulin-propionate ester, is safe for the general population under the proposed conditions of use.
应欧盟委员会的要求,欧洲食品安全局营养、新型食品及食品过敏原专家委员会(NDA)被要求根据欧盟法规(EU)2015/2283,就菊粉丙酸酯作为新型食品(NF)的安全性发表意见。本申请所涉及的新型食品是一种化合物,由主要由果糖部分组成的天然聚合物、多糖菊粉(65%-95% w/w)与短链脂肪酸(SCFA)部分丙酸(5%-35% w/w)酯化而成。该新型食品是通过菊粉与丙酸酐在碱性条件和控制温度下的化学反应合成的。该新型食品的目标人群为普通人群,拟用作谷物棒和水果奶昔类饮料的成分。基于所提供的对该新型食品代谢命运的研究,专家委员会认为该新型食品不会完整吸收,而是主要在大肠中代谢为菊粉和丙酸,然后分别呈现不可消化膳食纤维和短链脂肪酸的正常代谢命运。考虑到该新型食品的物理化学性质、生产工艺和代谢命运均未引发安全问题,并且鉴于丙酸及其盐类先前已由欧洲食品安全局ANS专家委员会(2014年)评估,以及有大量关于菊粉的安全数据,专家委员会认为无需对该新型食品进行遗传毒性和亚慢性毒理学研究。尽管所提供的人体研究存在局限性(主要旨在研究功效终点),专家委员会注意到,该新型食品在每日剂量高达20克、持续时间长达12个月的情况下,似乎总体耐受性良好。专家委员会得出结论,在所提议的使用条件下,新型食品菊粉丙酸酯对普通人群是安全的。